CDX Cell Lines

Custom Model Generation Services
Preclinical Testing Services
Bioanalytical ServicesPhenotyping ServicesAnti-Tumor Drug Efficacy EvaluationNon-GLP Toxicity Assessment ServicesMetabolic Disease Efficacy EvaluationAutoimmune Disease Efficacy EvaluationNeurodegenerative Disease Efficacy EvaluationCell Therapy & Gene Therapy Efficacy Evaluation
Germ-Free and Microbiome Services
Mouse-Derived Gut Microbiota LibraryCustomized Germ-free ServicesEvaluation of Anti-tumor Effect of Gut MicrobiotaMicrobiota Extraction and TransplantationGerm-free Rederivation and BreedingMicrobial Strain Culture and Colonization
Cell Lines and Customization Services
Cell Line Customization ServicesSyngeneic Cell LinesReporter Cell LinesCDX Cell Lines
Custom Breeding Services
Customized Mice Breeding ServicesCryopreservation and ResuscitationAssisted ReproductionMouse Rederivation Service
Animal Quality Testing Services
SNP Testing ServicesMicrobiology Testing ServicesGenetic IntegrityAnimal HealthAnimal Welfare
Assay Capabilities
Molecular PlatformPK/PD PlatformPathological Diagnosis PlatformCell-based Service PlatformFlow Cytometry PlatformImaging and Analysis PlatformBehavioral Analysis Platform
NeoMab Fully-Human Antibody Discovery Service
Other Services
Animal Facility and HusbandryReproductive and Embryology Services Isolation of Embryonic Fibroblasts

Cell line-derived xenograft models (CDX models) are in vivo models where human-derived tumor cells are transplanted into the subcutis of mice for efficacy evaluation or tumor-related research; It is one of the most frequently used in vivo models for preclinical analyses of anticancer medicines.

GemPharmatech's extensive selection of CDX cell lines, including pancreatic cancer, breast cancer, colon cancer, lung cancer, and lymphoma, can accommodate the requirements of various pharmacodynamic and efficacy investigations. On top of this wide selection, GemPharmatech has engineered 32 CDX cell lines with luciferase to enable non-invasive tumor volume analysis using bioluminescence. 


Cancer TypeUnmodified Cell LineLuciferase-Tagged Cell Line
AdemocarcimomaCalu-3, NCI-H1666, NCI-H441,NCI-H1650
Acute Myeloid LeukemiaMOLM13, OCIAML3
Anaplastic CarcinomaCalu-6
Barett AdenocarcinomaOE33
Bladder CancerUM-UC-3, HT1376, RT4, T24, RT112/84
Brain CancerU251, U-87 MG
Breast CancerBT-20, BT-474, BT-549, HCC1937, HCC1954, HCC1569, Hs 578T, JIMT-1, MCF7, MDA-MB-175VII, MDA-MB-231, MDA-MB-436, MDA-MB-453, MDA-MB-468, SK-BR-3, HCC70, T47DMDA-MB-468-Luc, MDA-MB-231-Luc, MCF-Luc
ChondrosarcomaSW1353
Clear Cell CarcinomaEs-2
Colorectal CancerColo205, HCT-116, HT29, HT-55,  LoVo, LS174T, RKO, SW48
Colorectal Cancer; Dukes' Type CLs1034
Colorectal Cancer; Dukes' Type C, Grade IIISW948
Colorectal Cancer; Dukes' Type BSW480
Colon Cancer
HT-29-Luc, HCT116-Luc, RKO-Luc
Colon AdenocarcinomaCOLO-320
Duodenal CancerHuTu 80
Endometrial CarcinomaHEC-1-A
EsophagusKYSE-150
Gastric CancerHs 746T, MKN45, NCI-N87, SGC-7901, SNU-16, KATOIII, NUGC4
Glioblastoma
U251-Luc, U87 MG-Luc
LeukemiaHL-60, Jurkat, K562, MOLT-4, MV-4-11, Nalm-6, SUP-B15, THP-1, CCRF-CEM, Hut78, TF1, Hs 505.TNalm6-Luc, K562-Luc, MOLM 13-Luc, HL60-Luc, MV-4-11-Luc, Jurkat-Luc
Liver CancerHepG2, Huh7Huh7-Luc, HepG2-Luc
Lung Cancer
A549-Luc, NCI-H82, NCI-H2171
LymphomaU937, NK92, Jeko-1, Daudi, Ramos, JVM-2, KAPPAS 299, Raj, SU-DHL-10, SU-DHL-16, U-2932, L-540Raji-Luc, U-937-Luc, MM.1S-Luc, Jeko-Luc, Thp-1-Luc, Daudi-Luc, Ramos
MelanomaA375, COLO829, SK-MEL-28, SK-MEL-5A375-Luc
Multiple MyelomaNCI-H929, MM.1R, MOLP-8, RPMI-8226,  MM.1SRPMI8226-Luc
NeuroblastomaIMR-32, SK-N-BE(2)
NSCLCA549, HCC-827, NCI-H1703, NCI-H1755, NCI-H1975, NCI-H2122, NCI-H358, NCI-H460, NCI-H1299, NCI-H647
OsteosarcomaMG63
Ovarian CancerOVCAR-3, SK-OV-3, TOV-112DSKOV3-Luc, OVCAR-Luc
Pancreatic CancerAsPC-1, BxPC-3, CAPAN-1, CFPAC-1, HPAC, MIA PaCa-2, PANC-1, SW1990PANC-Luc
PlasmacytomaU-266
Prostate Cancer22RV1, LNCaP, PC-3, LNCaP C4-2B
Pulmonary Mucoepidermoid CarcinomaNCI-H226, NCI-H292, NCI-H727, NCI-H69
Renal CarcinomaACHN, 786-O
SarcomaHT1080, SJSA-1, U-2 OS
SCLCDMS-53, NCI-2171, NCI-H446, NCI-H526, NCI-H82, SHP-77
Skin CancerA431
Submandibular Adenosquamous CarcinomaA253
Squamous Cell CarcinomaFaDu
TeratocarcinomaPA-1
Tongue Squamous Cell CarcinomaCal 27
Uterine Cancer
HEC-1-A-Luc


TALK WITH OUR EXPERTS

GemPharmatech is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please click below to say how you would like us to contact you:

In order to provide you with the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please click the checkbox below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.